Hansen, Morten1; Sonne, David Peick2; Mikkelsen, Kristian Hallundbæk3; Gluud, Lise Lotte4; Vilsbøll, Tina2; Knop, Filip Krag2
1 Department of Haematology, Herlev and Gentofte Hospital, The Capital Region of Denmark2 Internal Medicine, Gentofte, Herlev and Gentofte Hospital, The Capital Region of Denmark3 Medicinsk Afdeling F og Akutklinik4 Gastrounit, Medical Division, Gastrounit, Amager and Hvidovre Hospital, The Capital Region of Denmark
protocol for a systematic review with meta-analysis of randomised controlled trials
In addition to the lipid-lowering effect of bile acid sequestrants (BASs), they also lower blood glucose and, therefore, could be beneficial in the treatment of patients with type 2 diabetes mellitus (T2DM). Three oral BASs are approved by the US Food and Drug Administration (FDA) for the treatment of hypercholesterolaemia: colestipol, cholestyramine and colesevelam. The BAS colestimide/colestilan is used in Japan. Colesevelam was recently approved by the FDA for the treatment of T2DM. We plan to provide a systematic review with meta-analysis of the glucose-lowering effect of BASs with the aim to evaluate their potential as glucose-lowering agents in patients with T2DM.